

## References

### I-100

1. Erbitux (cetuximab) injection, for intravenous use [package insert]. Eli Lilly and Company. Indianapolis, IN. Revised 04/2021.
2. Lin L, Chen L, Wang Y, et al. Efficacy of cetuximab-based chemotherapy in metastatic colorectal cancer according to RAS and BRAF mutation subgroups: A meta- *Molecular and Clinical Oncology*. 2016; 4: 1017-1024.
3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Penile cancer. Version 2.2016.
4. MICROMEDEX®SOLUTIONS Compendia. 2021. Cetuximab.
5. Clinical Pharmacology Compendia [database online]. Tampa FL: Gold Standard, Inc. Cetuximab. 2021
6. National Comprehensive Cancer Network (NCCN). Cetuximab. NCCN Drugs and Biologics Compendium®. 2021.
7. Privitera G, Luca T, Musso N, et al. In vitro antiproliferative effect of trastuzumab (Herceptin) combined with cetuximab (Erbitux\_) in a model of human non-small cell lung cancer expressing EGFR and HER2. *Clin Exp Med*. 2016;16:161–168.
8. Carvalho AC, Leal F, Sasse AD. Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer. *PLoS ONE*. 12(4):e0175409.
9. Lieu CH, Messersmith WA. Cetuximab or Bevacizumab With First-Line Chemotherapy in Advanced KRAS Wild-Type Colorectal Cancer No Difference, but Not the Same. *JAMA*. 2017;2376-2378.
10. Saraswathula A, Chen MM, Colevas AD, Divi V. Assessing care value for older patients receiving radiotherapy with or without cisplatin or cetuximab for locoregionally advanced head and neck cancer. *JAMA Otolaryngology-Head & Neck Surgery*. 2019;145(12):1160-1167.
11. Zheng B, Wang X, Wei M, et al. First-line cetuximab versus bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: a systematic review and meta-analysis. *BMC Cancer*. 2019;19(1):1-12.
12. Lexi-Drugs. Hudson, OH: Lexicomp, 2021
13. [Cetuximab] In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. 2021
14. Heinemann V, Von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial. *Br J Cancer*. 2021;124(1): 587–594.

15. Montaudié H, Viotti J, Combemale P, et al. Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study. *Oncotarget* 2020;11(4):378-85.
16. Liu S, Jiang C, Yang L, et al. First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study. *Scientific reports*.2020; 10(1): 1-12.